Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Tremelimumab with CCRT for Inoperable Esophageal Squamous Cell Carcinoma
NCT03377400Phase 2Unknown
- Sponsor
- Samsung Medical Center
- Start
- Dec 2017
- Primary completion
- Jun 2021
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, tremelimumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Samsung Medical Center. Status: unknown.
02
Drugs
durvalumabtremelimumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT03377400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03377400.